Jazz Pharmaceuticals plc announced positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness in adults with narcolepsy at the World Sleep Meeting in Vancouver, Canada.

JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92% less sodium than Xyrem^® (sodium oxybate).

JZP-258 achieves primary and key secondary endpoints demonstrating highly statistically significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo.

To read more about the findings, go here.